2076975 2077203
최종편집 2024-03-29 23:03 (금)
Clopidogrel + Aspirin combination market shrinks YoY
상태바
Clopidogrel + Aspirin combination market shrinks YoY
  • Hyeokgi Lee, Newsmp
  • 승인 2021.06.28 15:28
  • 댓글 0
이 기사를 공유합니다

5.583 billion won in 1Q, ↓ 140 million won YoY… Only 3 products worth 1 billion won mark per quarter

The combinations of Clopidogrel and Aspirin, which each dreamed of becoming a blockbuster in the early stages of release, are still in a lull.

Far from blockbuster, it seems like products with quarterly sales of 1 billion won are unlikely to remain, if the current trend continues.

According to IQVIA, the market for Clopidogrel + Aspirin drugs in 1Q was about 5.6 billion won, down more than 100 million won from a year earlier.

Compared to those who were confident of selling tens of billions of sales at the time of launch, they look infinitely small.

As the Clopidogrel market is well over 200 billion won, each leading product was positive in sales of 30 billion to 50 billion won mark when the Clopidogrel + Aspirin combination market was first released.

However, even after nearly 10 years have passed since the Clopidogrel + Aspirin combination market opened, the market is at a standstill.

Some products recorded more than 10 billion won in outpatient prescription per year in the UBIST tally, but in the IQVIA tally, it is not easy to exceed 5 billion won per year.

In the first quarter, there were only three Clopidogrel + Aspirin combination drugs that made more than 1 billion won in sales. 

Superpirin (Myung In Pharm), the market leader, maintained sales of 1.3 billion won, but Clopirin (Jeil Pharmaceutical) and Plavix A (Sanofi Aventis) hardly managed the 1 billion won mark as sales decreased.

Among them, Plavix A had risen to the top of the market in 2019, but it has recently fallen to third place.

Following them, Closone (HK inno.N), which had been looking at the 1 billion won mark while keeping the 900 million won mark, was pushed back to the 800 million won mark in 1Q.

Clopigrel Duo (Celltrion Pharm), Clavixin Duo (Korea United Pharm), Pidogul A (Hanmi Pharmaceutical), and Copregrel (Chong Kun Dang Pharmaceutical) stayed in the early 200 million won mark.

Meanwhile, Clopidogrel + Aspirin combination drugs counted in IQVIQ were 32 products, and only 8 items achieved sales of over 100 million won in 1Q.

Even 12 of the 32 products, more than a third, were not counted in the first quarter.

It will be the 10th year of the market opening in March next year, but it seems difficult to find a clue for a rebound.  


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.